Korde, N., Mastey, D., Tavitian, E., Mailankody, S., Lesokhin, A., Hassoun, H., Smith, E. L., Lendvai, N., Hultcrantz, M., Shah, U., Tan, C., Lu, S., Diamond, B., Salcedo, M., Werner, K., Chung, D. J., Scordo, M., Shah, G. L., Lahoud, O., Landau, H., Arcila, M., Ho, C., Roshal, M., Dogan, A., Derkach, A., Devlin, S. M., Giralt, S. A., & Landgren, O. (2021). tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. American journal of hematology, 96(6), E193–E196. http://access.bl.uk/ark:/81055/vdc_100130155070.0x00004b